Cardinal Health, McKesson Double Down on CVS Deals Through 2032
Cardinal Health Inc. (NYSE: CAH ) on Thursday entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health Inc. (NYSE: CVS ) through June 30, 2032. Distribution Partnership With CVS Health The extension reflects the continuation of Cardinal Health’s current scope of distribution services. Read Also: Cardinal Health Says It Now Exclusively Serves Nearly Half The Cell-And-Gene Therapy Market In connection with the renewal, Cardinal Health has reaffirmed its fiscal year 2027 adjusted earnings growth guidance of 13% to 15%, equivalent to $12.40-$12.60 per share compared to the consensus of $12.04. The healthcare distributor company reiterates long-term adjusted earnings per share growth rate guidance of 12% to 14%. McKesson Signs Parallel CVS Agreement On Thursday, McKesson Corporation (NYSE: MCK ) also signed an agreement to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and distribution centers through June 2032. McKesson reiterated its fiscal 2027 adjusted earnings outlook between $44.20 and $45 per share, and its long-term adjusted EPS growth rate of 13% to 16%.
Cardinal Health Inc. (NYSE: CAH ) on Thursday entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health Inc. (NYSE: CVS ) through June 30, 2032. Distribution Partnership With CVS Health The extension reflects the continuation of Cardinal Health’s current scope of distribution services.
04. The healthcare distributor company reiterates long-term adjusted earnings per share growth rate guidance of 12% to 14%. McKesson Signs Parallel CVS Agreement On Thursday, McKesson Corporation (NYSE: MCK ) also signed an agreement to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and distribution centers through June 2032. 20 and $45 per share, and its long-term adjusted EPS growth rate of 13% to 16%.
Read Also: McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization In September, Aetna, a healthcare subsidiary of CVS Health, expanded its prior authorization bundles across all cancer types for members in eligible Medicaid states starting September 1. The health plan operator plans to eventually extend these bundled approvals across all lines of business by 2027. The initiative builds on the initial rollout’s success, in which nearly 25% of eligible members received a bundled prior authorization. 05 at the time of publication on Thursday, according to Pro data.
Read Also: Oracle Lands $7 Billion Tencent AI Deal — Chinese Tech Giant to Access 100,000 Advanced Chips Through Southeast Asia Data Centers: Report Photo via Shutterstock